Difference between revisions of "Team:Shanghai Metro Utd"
| (2 intermediate revisions by the same user not shown) | |||
| Line 27: | Line 27: | ||
<li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Description" | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Description" | ||
class="sub-nav-74">Description</a></li> | class="sub-nav-74">Description</a></li> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Experiments" | ||
| + | class="sub-nav-74">Experiments</a></li> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Results" | ||
| + | class="sub-nav-74">Results</a></li> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Proof_Of_Concept" | ||
| + | class="sub-nav-52">Proof Of | ||
| + | Concept</a></li> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Notebook" | ||
| + | class="sub-nav-52">Notebook</a> | ||
| + | </li> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Safety">Safety</a></li> | ||
| + | </ul> | ||
| + | </div> | ||
</li> | </li> | ||
| − | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/ | + | <li> |
| − | + | <a href="">Parts</a> | |
| − | + | <div class="sub-nav"> | |
| − | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/ | + | <ul> |
| − | + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Parts" class="sub-nav-74">Parts | |
| − | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/ | + | Collection</a></li> |
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Engineering" | ||
| + | class="sub-nav-74">Engineering</a></li> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Contribution" | ||
| + | class="sub-nav-74">Contribution</a></li> | ||
| + | </ul> | ||
| + | </div> | ||
| + | </li> | ||
| + | <li> | ||
| + | <a href="">Human Practices</a> | ||
| + | <div class="sub-nav"> | ||
| + | <ul> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Human_Practices" | ||
| + | class="sub-nav-74">Integrated | ||
| + | Human Practice</a></li> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Communication" | ||
| + | class="sub-nav-74">Communication</a></li> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Fundraising" | ||
| + | class="sub-nav-74">Fundraising</a></li> | ||
| + | </ul> | ||
| + | </div> | ||
| + | </li> | ||
| + | <li> | ||
| + | <a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Implementation">Implementation</a> | ||
| + | </li> | ||
| + | <li> | ||
| + | <a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Entrepreneurship">Entrepreneurship</a> | ||
| + | </li> | ||
| + | <li> | ||
| + | <a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Model">Model</a> | ||
| + | </li> | ||
| + | <li> | ||
| + | <a href="">Team</a> | ||
| + | <div class="sub-nav"> | ||
| + | <ul> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Members" class="sub-nav-74">Team | ||
| + | Members</a></li> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Attributions" | ||
| + | class="sub-nav-74">Attributions</a></li> | ||
| + | <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Collaborations" | ||
| + | class="sub-nav-74">Collaborations</a></li> | ||
| + | </ul> | ||
| + | </div> | ||
</li> | </li> | ||
| − | |||
</ul> | </ul> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
</div> | </div> | ||
</nav> | </nav> | ||
<div class="home-content"> | <div class="home-content"> | ||
<div class="top-banner"> | <div class="top-banner"> | ||
| − | <img src="https://static.igem.org/mediawiki/2021/9/91/T-- | + | <img src="https://static.igem.org/mediawiki/2021/9/91/T--Shanghai_Metro_Utd--top.gif" /> |
</div> | </div> | ||
<div class="swiper-container top-swiper-container group-photo"> | <div class="swiper-container top-swiper-container group-photo"> | ||
<div class="swiper-wrapper"> | <div class="swiper-wrapper"> | ||
<div class="swiper-slide"> | <div class="swiper-slide"> | ||
| − | <img src="https://static.igem.org/mediawiki/2021/2/20/T-- | + | <img src="https://static.igem.org/mediawiki/2021/2/20/T--Shanghai_Metro_Utd--homepage01.png" /> |
</div> | </div> | ||
<div class="swiper-slide"> | <div class="swiper-slide"> | ||
| − | <img src="https://static.igem.org/mediawiki/2021/f/fa/T-- | + | <img src="https://static.igem.org/mediawiki/2021/f/fa/T--Shanghai_Metro_Utd--homepage02.png" /> |
</div> | </div> | ||
<div class="swiper-slide"> | <div class="swiper-slide"> | ||
| − | <img src="https://static.igem.org/mediawiki/2021/f/fe/T-- | + | <img src="https://static.igem.org/mediawiki/2021/f/fe/T--Shanghai_Metro_Utd--homepage03.png" /> |
</div> | </div> | ||
</div> | </div> | ||
| Line 121: | Line 126: | ||
</div> | </div> | ||
<video width="100%" height="769" controls class="home-video"> | <video width="100%" height="769" controls class="home-video"> | ||
| − | <source src="https://static.igem.org/mediawiki/2021/9/93/T-- | + | <source src="https://static.igem.org/mediawiki/2021/9/93/T--Shanghai_Metro_Utd--video.mp4" type="video/mp4"> |
</video> | </video> | ||
</div> | </div> | ||
Latest revision as of 19:11, 19 October 2021
ABSTRACT
Parkinson’s disease (PD) is an inflammatory brain disease that affects 20 million people worldwide and the incidence is expected to rise. However, current medical treatment is not optimal, and thus an effective treatment is very much needed. Surprisingly, we discovered that a specific protein called Angiogenin is reported as a potential therapeutic target to neurodegenerative disease given. In this project, our team Healers on Vessels aim to construct a recombinant E. coli by biomedical engineering that can continuously synthesize functional ANG protein, which could possibly serve as an in vitro method to massive produce ANG for clinical use.